Investigational drug · Phase 3
Tolebrutinib
Also called: SAR442168
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
13
Any phase or sponsor naming "Tolebrutinib"
First trial start
2019
Sep 23, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tolebrutinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsing Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Progressive Relapsing Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tolebrutinib" as an intervention, largest first.
SanofiSanofi (SNY)
NCT07898371 · 3,000 participants (planned) · Start Oct 1, 2026 · Primary completion Sep 21, 2031
Drug: Tolebrutinib · For: Multiple Sclerosis
Sites: Marina, United Arab Emirates
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06372145 · 2,500 participants (planned) · Start Apr 16, 2024 · Primary completion Apr 30, 2029
Drug: Tolebrutinib; Placebo and 1 more · For: Relapsing Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Progressive Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 352 sites in all
- Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04411641 · 1,131 participants · Start Sep 24, 2020 · Primary completion Aug 29, 2024
Drug: Tolebrutinib; Placebo to match Tolebrutinib · For: Non-relapsing Secondary Progressive Multiple Sclerosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Arcadia, California · 306 sites in all
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04410978 · 974 participants · Start Jun 30, 2020 · Primary completion Jul 15, 2024
Drug: Tolebrutinib; Teriflunomide and 2 more · For: Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; San Francisco, California; Aurora, Colorado · 179 sites in all
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04410991 · 899 participants · Start Jun 11, 2020 · Primary completion Jul 16, 2024
Drug: Tolebrutinib; Teriflunomide HMR1726 and 2 more · For: Relapsing Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; Arcadia, California · 186 sites in all
- Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04458051 · 767 participants · Start Aug 13, 2020 · Primary completion Nov 14, 2025
Drug: Tolebrutinib; Placebo · For: Primary Progressive Multiple Sclerosis
Sites: La Jolla, California; Los Alamitos, California; Los Angeles, California · 277 sites in all
SanofiSanofi (SNY)
NCT03996291 · 125 participants · Start Sep 23, 2019 · Primary completion Nov 26, 2024
Drug: Tolebrutinib · For: Relapsing Multiple Sclerosis
Sites: Cullman, Alabama; Maitland, Florida; Tampa, Florida · 37 sites in all
SanofiSanofi (SNY)
NCT06106074 · 71 participants · Start Aug 10, 2020 · Primary completion May 23, 2022
Drug: Tolebrutinib; Placebo · For: Multiple Sclerosis
Sites: Knoxville, Tennessee
SanofiSanofi (SNY)
NCT06064539 · 30 participants · Start May 18, 2020 · Primary completion Jul 8, 2020
Drug: Tolebrutinib; gemfibrozil and 1 more · For: Multiple Sclerosis
Sites: Saint Paul, Minnesota
SanofiSanofi (SNY)
NCT05282030 · 22 participants · Start Mar 10, 2022 · Primary completion Aug 2, 2022
Drug: tolebrutinib · For: Renal Impairment
Sites: Miami, Florida; Saint Paul, Minnesota; Knoxville, Tennessee · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model.
Centonze D, Calabrese M, Cocco E, et al. · Neurol Ther 2026
- Erratum to "Tolebrutinib liver safety: A detailed overview" [Multiple Sclerosis and Related Disorders 113 (2026) 107404].
Maxwell CR, Turner TJ, Wallstroem E, et al. · Mult Scler Relat Disord 2026
- Efficacy and safety of tolebrutinib in multiple sclerosis: a systematic review and meta-analysis.
Mosad N, Roshdy Y, Emad T, et al. · Neurol Sci 2026
- From Global Evidence to Saudi Practice: A Structured Evidence Map of the Diagnosis, Molecular Targets, and Therapeutic Strategies of Multiple Sclerosis in the Kingdom of Saudi Arabia.
Mir R, Algehainy NA, Jalal MM, et al. · Diseases 2026
- Tolebrutinib in nonrelapsing SPMS: regulatory divergence and the limits of relapse based labels.
Niu T, Li J, Wang Q, et al. · Mult Scler Relat Disord 2026
- Tolebrutinib liver safety: A detailed overview.
Maxwell CR, Turner TJ, Wallstroem E, et al. · Mult Scler Relat Disord 2026
Also in development for Relapsing Multiple Sclerosis
- FenebrutinibRO7010939, GDC-0853Phase 36 trials
Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
- PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.